期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 15, 期 12, 页码 1367-1369出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1110488
关键词
fibroblast growth factor receptor; kidney; personalized medicine; precision medicine; renal cell carcinoma; targeted therapy; vascular endothelial growth factor receptor
类别
Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据